STK11 and lung carcinoma: These studies again demonstrate that pharmaceutical inhibition of BMP signaling in combination with a mitochondrial inhibitor enhances AMPK activation and synergistically suppresses growth and induces cell death of LKB1 competent lung cancer cells.